Ilio Vitale

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5228317/publications.pdf

Version: 2024-02-01

131 papers	24,236 citations	31976 53 h-index	16650 123 g-index
131 all docs	131 docs citations	131 times ranked	35739 citing authors

#	Article	IF	Citations
1	Catastrophic DNA replication in unscheduled tetraploid cells. Trends in Genetics, 2022, 38, 787-788.	6.7	5
2	Oncosuppressive functions of PIDD1 in response to centrosome amplification. Cell Death and Disease, 2021, 12, 175.	6.3	0
3	Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nature Medicine, 2021, 27, 212-224.	30.7	376
4	Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51. Cell Death and Differentiation, 2021, 28, 2060-2082.	11.2	19
5	Relative Information Gain: Shannon entropy-based measure of the relative structural conservation in RNA alignments. NAR Genomics and Bioinformatics, 2021, 3, lqab007.	3.2	3
6	The Targeting of MRE11 or RAD51 Sensitizes Colorectal Cancer Stem Cells to CHK1 Inhibition. Cancers, 2021, 13, 1957.	3.7	8
7	BRIO: a web server for RNA sequence and structure motif scan. Nucleic Acids Research, 2021, 49, W67-W71.	14.5	10
8	Using epigenetic modifiers to target cancer stem cell immunoevasion. Cancer Cell, 2021, 39, 1573-1575.	16.8	7
9	Cytofluorometric assessment of dendritic cell-mediated uptake of cancer cell apoptotic bodies. Methods in Enzymology, 2020, 632, 39-54.	1.0	1
10	Immunological impact of cell death signaling driven by radiation on the tumor microenvironment. Nature Immunology, 2020, 21, 120-134.	14.5	218
11	Caspase 2 and p53 Reunited in Tumor Control. Trends in Cell Biology, 2020, 30, 917-918.	7.9	0
12	Tuning Cancer Fate: Tumor Microenvironment's Role in Cancer Stem Cell Quiescence and Reawakening. Frontiers in Immunology, 2020, 11, 2166.	4.8	60
13	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
14	Macrophages and Metabolism in the Tumor Microenvironment. Cell Metabolism, 2019, 30, 36-50.	16.2	933
15	Stress responses in stromal cells and tumor homeostasis. , 2019, 200, 55-68.		22
16	Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. Trends in Cell Biology, 2019, 29, 396-416.	7.9	66
17	Oncogene-induced senescence and tumour control in complex biological systems. Cell Death and Differentiation, 2018, 25, 1005-1006.	11.2	110
18	The clinical significance of PD-L1 in advanced gastric cancer is dependent onARID1Amutations and ATM expression. OncoImmunology, 2018, 7, e1457602.	4.6	11

#	Article	IF	Citations
19	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 2018, 25, 486-541.	11.2	4,036
20	Everybody In! No Bouncers at Tumor Gates. Trends in Genetics, 2018, 34, 85-87.	6.7	3
21	CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. Gut, 2018, 67, 903-917.	12.1	64
22	Calcium signaling and cell cycle: Progression or death. Cell Calcium, 2018, 70, 3-15.	2.4	152
23	Replication stress response in cancer stem cells as a target for chemotherapy. Seminars in Cancer Biology, 2018, 53, 31-41.	9.6	31
24	DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. International Journal of Cancer, 2017, 140, 2587-2595.	5.1	30
25	Body mass index modifies the relationship between Î³-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. BMC Cancer, 2017, 17, 101.	2.6	12
26	Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications. OncoImmunology, 2017, 6, e1314424.	4.6	106
27	DNA Damage in Stem Cells. Molecular Cell, 2017, 66, 306-319.	9.7	259
28	Spontaneous DNA damage propels tumorigenicity. Cell Research, 2017, 27, 720-721.	12.0	4
29	Caspase 2 in mitotic catastrophe: The terminator of aneuploid and tetraploid cells. Molecular and Cellular Oncology, 2017, 4, e1299274.	0.7	24
30	Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression. Scientific Reports, 2017, 7, 8078.	3.3	14
31	Driving to Cancer on a Four-Lane Expressway. Trends in Genetics, 2017, 33, 491-492.	6.7	5
32	Synchronization and Desynchronization of Cells by Interventions on the Spindle Assembly Checkpoint. Methods in Molecular Biology, 2017, 1524, 77-95.	0.9	2
33	Signal Transduction Networks Analysis: The Reverse Phase Protein Array. , 2017, , .		0
34	Molecular Regulation of the Spindle Assembly Checkpoint by Kinases and Phosphatases. International Review of Cell and Molecular Biology, 2017, 328, 105-161.	3.2	38
35	ATM kinase sustains breast cancer stem-like cells by promoting ATG4C expression and autophagy. Oncotarget, 2017, 8, 21692-21709.	1.8	39
36	Molecular Mechanisms of Immunogenic Cell Death. , 2017, , .		0

#	Article	IF	Citations
37	Replication stress in colorectal cancer stem cells. Oncotarget, 2017, 8, 90606-90607.	1.8	1
38	Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment. OncoImmunology, 2016, 5, e1160187.	4.6	30
39	Cytofluorometric Quantification of Cell Death Elicited by NLR Proteins. Methods in Molecular Biology, 2016, 1417, 231-245.	0.9	1
40	LTX-315, CAPtivating immunity with necrosis. Cell Cycle, 2016, 15, 1176-1177.	2.6	3
41	Trial watch â€“ inhibiting PARP enzymes for anticancer therapy. Molecular and Cellular Oncology, 2016, 3, e1053594.	0.7	19
42	DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis. PLoS ONE, 2016, 11, e0149872.	2.5	11
43	Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition. Oncotarget, 2016, 7, 885-901.	1.8	31
44	The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications. Expert Reviews in Molecular Medicine, 2015, 17, e14.	3.9	75
45	Role of autophagy in the maintenance and function of cancer stem cells. International Journal of Developmental Biology, 2015, 59, 95-108.	0.6	35
46	Trial Watch: Proteasomal inhibitors for anticancer therapy. Molecular and Cellular Oncology, 2015, 2, e974463.	0.7	18
47	Trial Watch: Targeting ATMâ€“CHK2 and ATRâ€“CHK1 pathways for anticancer therapy. Molecular and Cellular Oncology, 2015, 2, e1012976.	0.7	117
48	Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer. Annals of Oncology, 2015, 26, 2470-2477.	1.2	20
49	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science, 2015, 350, 972-978.	12.6	367
50	Karyotypic Aberrations in Oncogenesis and Cancer Therapy. Trends in Cancer, 2015, 1, 124-135.	7.4	28
51	Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death and Differentiation, 2015, 22, 58-73.	11.2	811
52	Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. Oncotarget, 2015, 6, 42773-42780.	1.8	14
53	Autocrine signaling of type 1 interferons in successful anticancer chemotherapy. OncoImmunology, 2015, 4, e988042.	4.6	27
54	Consensus guidelines for the detection of immunogenic cell death. OncoImmunology, 2014, 3, e955691.	4.6	686

#	Article	IF	Citations
55	Trial Watch: Radioimmunotherapy for oncological indications. OncoImmunology, 2014, 3, e954929.	4.6	40
56	Chloroquine and hydroxychloroquine for cancer therapy. Molecular and Cellular Oncology, 2014, 1, e29911.	0.7	154
57	Predictive biomarkers for cancer therapy with PARP inhibitors. Oncogene, 2014, 33, 3894-3907.	5.9	89
58	Resveratrol and aspirin eliminate tetraploid cells for anticancer chemoprevention. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3020-3025.	7.1	59
59	Systems biology of cisplatin resistance: past, present and future. Cell Death and Disease, 2014, 5, e1257-e1257.	6.3	625
60	Cancer cellâ€“autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nature Medicine, 2014, 20, 1301-1309.	30.7	823
61	PARP and other prospective targets for poisoning cancer cell metabolism. Biochemical Pharmacology, 2014, 92, 164-171.	4.4	24
62	MCL-1 dependency of cisplatin-resistant cancer cells. Biochemical Pharmacology, 2014, 92, 55-61.	4.4	54
63	Characterization of novel MPS1 inhibitors with preclinical anticancer activity. Cell Death and Differentiation, 2013, 20, 1532-1545.	11.2	88
64	Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. Cell Cycle, 2013, 12, 877-883.	2.6	57
65	Effects of vitamin B6 metabolism on oncogenesis, tumor progression and therapeutic responses. Oncogene, 2013, 32, 4995-5004.	5.9	108
66	Cytofluorometric Assessment of Cell Cycle Progression. Methods in Molecular Biology, 2013, 965, 93-120.	0.9	10
67	Prognostic value of LIPC in non-small cell lung carcinoma. Cell Cycle, 2013, 12, 647-654.	2.6	16
68	An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells. OncoImmunology, 2013, 2, e22409.	4.6	20
69	Cisplatin Resistance Associated with PARP Hyperactivation. Cancer Research, 2013, 73, 2271-2280.	0.9	143
70	Immunosurveillance against tetraploidization-induced colon tumorigenesis. Cell Cycle, 2013, 12, 473-479.	2.6	36
71	Vitamin B6 metabolism influences the intracellular accumulation of cisplatin. Cell Cycle, 2013, 12, 417-421.	2.6	26
72	Trial watch. OncoImmunology, 2013, 2, e25771.	4.6	150

#	Article	IF	Citations
73	Transgenerational cell fate profiling. Cell Cycle, 2013, 12, 183-190.	2.6	5
74	Trial Watch. OncoImmunology, 2013, 2, e25595.	4.6	83
75	Impact of the Ku Complex on HIV-1 Expression and Latency. PLoS ONE, 2013, 8, e69691.	2.5	22
76	Independent transcriptional reprogramming and apoptosis induction by cisplatin. Cell Cycle, 2012, 11, 3472-3480.	2.6	32
77	Tetraploid cancer cell precursors in ovarian carcinoma. Cell Cycle, 2012, 11, 3157-3158.	2.6	6
78	Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer. Cell Reports, 2012, 2, 257-269.	6.4	122
79	Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer. Cell Reports, 2012, 2, 1472.	6.4	0
80	Preferential killing of p53-deficient cancer cells by reversine. Cell Cycle, 2012, 11, 2149-2158.	2.6	34
81	An Immunosurveillance Mechanism Controls Cancer Cell Ploidy. Science, 2012, 337, 1678-1684.	12.6	367
82	Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death and Differentiation, 2012, 19, 107-120.	11.2	2,144
83	Molecular mechanisms of cisplatin resistance. Oncogene, 2012, 31, 1869-1883.	5.9	2,058
84	Selective killing of p53â€deficient cancer cells by SP600125. EMBO Molecular Medicine, 2012, 4, 500-514.	6.9	47
85	Autophagic removal of micronuclei. Cell Cycle, 2012, 11, 170-176.	2.6	162
86	Evaluation of Rapamycin-Induced Cell Death. Methods in Molecular Biology, 2012, 821, 125-169.	0.9	15
87	Immunosurveillance against cancer-associated hyperploidy. Oncotarget, 2012, 3, 1270-1271.	1.8	10
88	Abstract 3115: PARP overactivation predicts the susceptibility of human cancer cells to apoptosis induction by PARP inhibitors. , 2012, , .		0
89	Oncosuppressive Functions of Autophagy. Antioxidants and Redox Signaling, 2011, 14, 2251-2269.	5.4	86
90	Mitochondrial Liaisons of p53. Antioxidants and Redox Signaling, 2011, 15, 1691-1714.	5.4	66

#	Article	IF	Citations
91	Past, Present, and Future of Molecular and Cellular Oncology. Frontiers in Oncology, 2011, 1, 1.	2.8	20
92	Cell Death Signaling and Anticancer Therapy. Frontiers in Oncology, 2011, 1, 5.	2.8	46
93	Mitotic catastrophe: a mechanism for avoiding genomic instability. Nature Reviews Molecular Cell Biology, 2011, 12, 385-392.	37.0	682
94	Illicit survival of cancer cells during polyploidization and depolyploidization. Cell Death and Differentiation, 2011, 18, 1403-1413.	11.2	125
95	A fluorescence-microscopic and cytofluorometric system for monitoring the turnover of the autophagic substrate p62/SQSTM1. Autophagy, 2011, 7, 883-891.	9.1	36
96	Cytofluorometric Purification of Diploid and Tetraploid Cancer Cells. Methods in Molecular Biology, 2011, 761, 47-63.	0.9	5
97	IKK connects autophagy to major stress pathways. Autophagy, 2010, 6, 189-191.	9.1	46
98	Viral strategies for the evasion of immunogenic cell death. Journal of Internal Medicine, 2010, 267, 526-542.	6.0	53
99	A novel source of tetraploid cancer cell precursors: telomere insufficiency links aging to oncogenesis. Oncogene, 2010, 29, 5869-5872.	5.9	5
100	The IKK complex contributes to the induction of autophagy. EMBO Journal, 2010, 29, 619-631.	7.8	274
101	Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on Mos. EMBO Journal, 2010, 29, 1272-1284.	7.8	155
102	miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death. Cancer Research, 2010, 70, 1793-1803.	0.9	262
103	Involvement of p38Î± in the mitotic progression ofp53^{-/-}tetraploid cells. Cell Cycle, 2010, 9, 2895-2901.	2.6	8
104	Defective autophagy associated with LC3 puncta in epothilone-resistant cancer cells. Cell Cycle, 2010, 9, 377-383.	2.6	17
105	An automated fluorescence videomicroscopy assay for the detection of mitotic catastrophe. Cell Death and Disease, 2010, 1, e25-e25.	6.3	37
106	Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy. Cell Death and Disease, 2010, 1, e10-e10.	6.3	518
107	Mitochondrial gateways to cancer. Molecular Aspects of Medicine, 2010, 31, 1-20.	6.4	239
108	The life span-prolonging effect of Sirtuin-1 is mediated by autophagy. Autophagy, 2010, 6, 186-188.	9.1	127

#	Article	IF	Citations
109	Preferential killing of tetraploid tumor cells by targeting the mitotic kinesin Eg5. Cell Cycle, 2009, 8, 1030-1035.	2.6	40
110	p53 represses the polyploidization of primary mammary epithelial cells by activating apoptosis. Cell Cycle, 2009, 8, 1380-1385.	2.6	38
111	A chemical inhibitor of Apaf-1 exerts mitochondrioprotective functions and interferes with the intra-S-phase DNA damage checkpoint. Apoptosis: an International Journal on Programmed Cell Death, 2009, 14, 182-190.	4.9	31
112	The inositol 1,4,5-trisphosphate receptor regulates autophagy through its interaction with Beclin 1. Cell Death and Differentiation, 2009, 16, 1006-1017.	11.2	258
113	Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death and Differentiation, 2009, 16, 1093-1107.	11.2	599
114	Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines. Oncogene, 2009, 28, 4249-4260.	5.9	53
115	Disruption of the PP1/GADD34 complex induces calreticulin exposure. Cell Cycle, 2009, 8, 3971-3977.	2.6	38
116	The tubulin-depolymerising agent combretastatin-4 induces ectopic aster assembly and mitotic catastrophe in lung cancer cells H460. Apoptosis: an International Journal on Programmed Cell Death, 2008, 13, 659-669.	4.9	41
117	Regulation of autophagy by cytoplasmic p53. Nature Cell Biology, 2008, 10, 676-687.	10.3	1,025
118	Chapter Eighteen Methods to Dissect Mitochondrial Membrane Permeabilization in the Course of Apoptosis. Methods in Enzymology, 2008, 442, 355-374.	1.0	27
119	Methods for Assessing Autophagy and Autophagic Cell Death. Methods in Molecular Biology, 2008, 445, 29-76.	0.9	159
120	The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death and Differentiation, 2008, 15, 1499-1509.	11.2	298
121	Chk1 inhibition activates p53 through p38 MAPK in tetraploid cancer cells. Cell Cycle, 2008, 7, 1956-1961.	2.6	41
122	Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone. Cancer Research, 2008, 68, 5301-5308.	0.9	101
123	Cell Cycle-Dependent Induction of Autophagy, Mitophagy and Reticulophagy. Cell Cycle, 2007, 6, 2263-2267.	2.6	117
124	Depletion of Endonuclease G Selectively Kills Polyploid Cells. Cell Cycle, 2007, 6, 1072-1076.	2.6	29
125	Inhibition of Chk1 Kills Tetraploid Tumor Cells through a p53-Dependent Pathway. PLoS ONE, 2007, 2, e1337.	2.5	67
126	Regulation of autophagy by the inositol trisphosphate receptor. Cell Death and Differentiation, 2007, 14, 1029-1039.	11.2	285

#	Article	IF	Citations
127	Cell death modalities: classification and pathophysiological implications. Cell Death and Differentiation, 2007, 14, 1237-1243.	11.2	688
128	Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 155-166.	4.9	51
129	Apoptosis regulation in tetraploid cancer cells. EMBO Journal, 2006, 25, 2584-2595.	7.8	180
130	Selective Resistance of Tetraploid Cancer Cells against DNA Damage-Induced Apoptosis. Annals of the New York Academy of Sciences, 2006, 1090, 35-49.	3.8	50
131	Caspase-independent apoptosis is activated by diazepam-induced mitotic failure in HeLa cells, but not in human primary fibroblasts. Apoptosis: an International Journal on Programmed Cell Death, 2005, 10, 909-920.	4.9	12